GILDCongressional Stock Trades
Gilead Sciences Inc
Biological Products, (No Diagnostic Substances)
Congressional stock trades in Gilead Sciences Inc (GILD) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
17
Politicians Trading
9
Last Traded
Aug 10, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Ro KhannaD | Aug 7, 2026 | Jul 20, 2026 | Buy | $1,001 - $15,000 | +12.69% |
| Jared MoskowitzD | Jun 19, 2026 | May 6, 2026 | Buy | $1,001 - $15,000 | +10.13% |
| Jared MoskowitzD | Jun 19, 2026 | May 6, 2026 | Buy | $1,001 - $15,000 | +10.13% |
| Josh GottheimerD | Feb 26, 2026 | Jan 27, 2026 | Buy | $1,001 - $15,000 | +6.48% |
| Josh GottheimerD | Apr 10, 2025 | Mar 7, 2025 | Buy | $1,001 - $15,000 | +27.85% |
Price History
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).